Nuvectis Pharma (NVCT) Assets (2021 - 2026)
Nuvectis Pharma (NVCT) posted Assets of $25.4 million for Q1 2026, down 19.9% sequentially from $31.7 million in Q4 2025, and down 15.76% YoY from $30.1 million in Q1 2025.
Nuvectis Pharma (NVCT) Assets (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Assets for 6 years, with the latest figure at $25.4 million in Q1 2026.
- Quarterly Assets fell 15.76% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (down 15.76% YoY) and the FY2025 annual result came in at $31.7 million, up 70.41% from the prior year.
- Assets eased to $25.4 million in Q1 2026 per NVCT's latest filing, from $31.7 million in the prior quarter.
- Over five years, Assets peaked at $35.6 million in Q3 2025 and troughed at $14.2 million in Q2 2022.
- A 5-year average of $22.6 million and a median of $20.4 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets soared 206.52% in 2022, then decreased 26.63% in 2024.
- Over 5 years, Assets stood at $20.4 million in 2022, then declined by 5.98% to $19.2 million in 2023, then retreated by 3.01% to $18.6 million in 2024, then jumped by 70.41% to $31.7 million in 2025, then fell by 19.9% to $25.4 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $25.4 million, $31.7 million, and $35.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 22.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.38 Mn |
| Mar 31, 2026 | 25.40 Mn |
| Dec 31, 2025 | 31.71 Mn |
| Sep 30, 2025 | 35.59 Mn |
| Jun 30, 2025 | 27.01 Mn |
| Mar 31, 2025 | 30.15 Mn |
| Dec 31, 2024 | 18.61 Mn |
| Sep 30, 2024 | 17.31 Mn |
| Jun 30, 2024 | 18.30 Mn |
| Mar 31, 2024 | 19.71 Mn |
| Dec 31, 2023 | 19.19 Mn |
| Sep 30, 2023 | 22.26 Mn |
| Jun 30, 2023 | 24.94 Mn |
| Mar 31, 2023 | 16.21 Mn |
| Dec 31, 2022 | 20.41 Mn |
| Sep 30, 2022 | 24.87 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 17.62 Mn |
| Dec 31, 2021 | 6.66 Mn |